New treatment for people with alopecia
Alopecia areata is an autoimmune disease characterised by loss if hair in single or multiple areas of the scalp, face or body. The scalp is most commonly affected.
The purpose of this study is to compare the effects of the PF-06651600 with a placebo to find out which is better for treating alopecia areata. Researchers will compare the results of taking the placebo to the results of taking PF-06651600 to see if there are any differences.
Anticipated date that enrolment will close: TBA
Who can take part
- 12 years and over
- Clinical diagnosis of alopecia areat
- History of any progressive/sudden hearing loss.
- History of current malignancy except adequately treated or excised
- non metastatic basal cell carcinoma
- squamous cell carcinoma
- cervical carcinoma in situ
- History of lymphoproliferative disorder
What is involved for you
- 14 visits over 53 weeks
- blood/urine samples
- chest x-ray
- blood pressure